ERBB2 and gastric cancer: At present, the first-line biological agents for the treatment of gastric cancer include the HER2 antibodies, the anti-PD1 antibodies nivolumab and pembrolizumab, the anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab [39].